SCHEMBL7035348

SCHEMBL7035348

Cc1ccccc1C(=S)c1ccc(Nc2nc3ccccc3o2)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.55
RAB9A P51151 7/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
MAPT P10636 6/20 0.55
KMT2A Q03164 3/20 0.55
NPSR1 Q6W5P4 2/20 0.55
MEN1 O00255 2/20 0.55
PKM P14618 4/20 0.47
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
MAPK14 Q16539 6/20 0.45
MAPK13 O15264 5/20 0.45
MAPK12 P53778 5/20 0.45
MAPK11 Q15759 5/20 0.45
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7037869 0.87 MAPK13 (0.62) NPC1RAB9ASMN1; SMN2MAPTKMT2A
SCHEMBL7039478 0.85 MAPT (0.53) NPC1RAB9ASMN1; SMN2MAPTKMT2A
SCHEMBL7037904 0.78 MAPK14 (0.46) NPC1RAB9ASMN1; SMN2MAPTKMT2A
SCHEMBL1901734 0.77 MAPK14 (0.71) SMN1; SMN2MAPTKMT2ANPSR1MEN1
SCHEMBL11376781 0.77 NPC1 (0.64) NPC1RAB9ASMN1; SMN2MAPTKMT2A
SCHEMBL7032510 0.77 KDR (0.49) NPC1RAB9ASMN1; SMN2MAPTNPSR1
SCHEMBL1902533 0.77 MAPK14 (0.59) MAPTNPSR1MAPK14MAPK13MAPK12
SCHEMBL5174459 0.76 MAPK14 (0.71) MAPTNPSR1MAPK14MAPK13MAPK12
SCHEMBL1899616 0.76 MAPK14 (0.61) SMN1; SMN2MAPTKMT2ANPSR1MEN1
SCHEMBL7037765 0.76 NPC1 (0.52) NPC1RAB9ASMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP claimed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US claimed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US claimed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO claimed
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP disclosed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US disclosed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US disclosed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha IL1B, IL1A, NFKBIA NPC1 2436/4885RAB9A 3591/4885SMN1; SMN2 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.